These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22173067)

  • 21. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A template model for studying anticancer drug efflux transporter inhibitors in vitro.
    Sostelly A; Payen L; Guitton J; Di Pietro A; Falson P; Honorat M; Valdameri G; Geze A; Boumendjel A; Freyer G; Tod M
    Fundam Clin Pharmacol; 2013 Oct; 27(5):544-56. PubMed ID: 22882086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2.
    Zhao XQ; Dai CL; Ohnuma S; Liang YJ; Deng W; Chen JJ; Zeng MS; Ambudkar SV; Chen ZS; Fu LW
    Eur J Pharm Sci; 2013 Jun; 49(3):441-50. PubMed ID: 23619284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
    Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
    Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).
    Tan KW; Killeen DP; Li Y; Paxton JW; Birch NP; Scheepens A
    Eur J Pharmacol; 2014 Jan; 723():346-52. PubMed ID: 24269959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
    Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
    J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
    Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
    Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
    Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.
    Neumanova Z; Cerveny L; Ceckova M; Staud F
    AIDS; 2014 Jan; 28(1):9-17. PubMed ID: 24413260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N; Yuan J; Liu J; Tian S
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
    Ozvegy C; Váradi A; Sarkadi B
    J Biol Chem; 2002 Dec; 277(50):47980-90. PubMed ID: 12374800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
    Jabor Gozzi G; Bouaziz Z; Winter E; Daflon-Yunes N; Aichele D; Nacereddine A; Marminon C; Valdameri G; Zeinyeh W; Bollacke A; Guillon J; Lacoudre A; Pinaud N; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    J Med Chem; 2015 Jan; 58(1):265-77. PubMed ID: 25272055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
    Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
    J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
    Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW
    Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.